Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Photo Evaluation
The purpose of this study is to demonstrate the absence of photoirritation and photosensitization potential of the product Dermacyd PHDETINBACK Tangerine Mix (Lactic Acid)...
Brief Summary
Official Title: “Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DETINBACK Tangerine Mix”
The purpose of this study is to demonstrate the absence of photoirritation and photosensitization potential of the product Dermacyd PHDETINBACK Tangerine Mix (Lactic Acid).
- Study Type: Interventional
- Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
- Study Primary Completion Date: September 2008
Intervention(s) in this Clinical Trial
- Drug: Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
- Lactic Acid
Arms, Groups and Cohorts in this Clinical Trial
- Experimental: 1
- Lactic Acid
Outcome Measures for this Clinical Trial
Primary Measures
- The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale.
- Time Frame: Throughout the study
Safety Issue?: No
- Time Frame: Throughout the study
- The sensibility will be evaluated according to the skin type.
- Time Frame: Throghout the study
Safety Issue?: No
- Time Frame: Throghout the study
Criteria for Participation in this Clinical Trial
Inclusion criteria:
- Age between 18 and 60 years old;
- Phototype Skin II and III;
- Integral skin test in the region;
- Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion;
Exclusion criteria:
- Lactation or gestation
- Use of Antiinflammatory and/or immunossupression drugs 15 days before the selection;
- Diseases which can cause immunity decrease, such as HIV, diabetes;
- Use of drug photosensitizer;
- History of sensitivity or irritation for topic products;
- Active cutaneous disease which can change the study results;
- History of photodermatosis active;
- Family or personal antecedent of cutaneous photoinduced neoplasias;
- Presence of a precursor lesion of cutaneous neoplasia, such as nevus melanocyte and queratoses actinium;
- Intense solar exposure in the study area;
- Use of new drugs or cosmetics during the study
Gender Eligibility for this Clinical Trial: Female
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 60 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Investigator Information
Lead Investigator: Sanofi-Aventis Industry
Overall Clinical Trial Officials and Contacts
Jaderson Lima Study Director Sanofi-Aventis
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00783666
Study ID Number: LACAC_L_04309
ClinicalTrials.gov Identifier: NCT00783666
Health Authority: Brazil: National Health Surveillance Agency
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00783666
